LTR Pharma Locks in Exclusive US Pharmacy Partner for ROXUS Commercial Launch
LTR Pharma secures exclusive US pharmacy fulfilment partner for ROXUS®
LTR Pharma has executed a binding term sheet with Strive Specialties Inc., establishing exclusive US 503A pharmacy and fulfilment rights for ROXUS®. This represents a launch-readiness milestone for the company’s entry into the world’s largest erectile dysfunction market and materially reduces execution risk ahead of commercial launch.
Under the arrangement, LTR Pharma retains ownership of the product, intellectual property, and formulation supply, whilst Strive Pharmacy provides the pharmacy fulfilment infrastructure to dispense ROXUS prescriptions across the company’s US commercial channels.
When big ASX news breaks, our subscribers know first
What is a 503A pharmacy and why does it matter for ROXUS®?
Section 503A is a US FDA regulatory pathway that allows pharmacies to compound personalised medicines for individual patients based on prescriber orders. ROXUS® is supplied in the United States through the US Section 503A personalised medicine pathway.
For LTR Pharma, the 503A pathway provides faster market entry whilst maintaining regulatory compliance. The pathway suits ROXUS®’s positioning as a personalised treatment option, allowing the company to commercialise the product whilst avoiding the extensive timelines and costs associated with New Drug Applications.
Key commercial terms of the Strive Pharmacy arrangement
The agreement is a binding term sheet with defined binding elements including exclusivity, confidentiality, non-circumvention, payment, and service-level provisions. Broader commercial terms require Definitive Agreements within 30 days of the effective date, extendable once by a further 30 days by mutual agreement. If Definitive Agreements are not executed within that period, the term sheet terminates, except for the surviving binding provisions, and exclusivity ends automatically.
Key commercial terms include:
- Exclusivity: Strive Pharmacy holds sole US 503A pharmacy and fulfilment rights for ROXUS for the term, subject to ongoing performance
- Term: Two-year initial term from Commercial Launch, with annual auto-renewal unless either party elects not to renew
- Commercial channels: Multi-channel commercialisation strategy incorporating telehealth, pharmacy fulfilment, and healthcare provider networks
- Commercial launch: Subject to completion of technology transfer and pharmacy onboarding, and satisfaction of launch-readiness conditions
The exclusivity structure aligns partner incentives with LTR Pharma’s commercial success whilst maintaining performance accountability. The performance-based exclusivity ensures the arrangement remains mutually beneficial throughout the term.
The Strive Pharmacy arrangement complements the Shed telehealth partnership announced earlier in June, which targets 150,000 ROXUS prescription units in the first 12 months through Shed’s consumer-facing Mavrox men’s health platform, together forming the multi-channel commercialisation strategy LTR Pharma has outlined for the US market.
Strive Pharmacy’s national fulfilment infrastructure
Strive Specialties Inc operates as a US-based personalised medicine and 503A pharmacy with an established multi-state platform across five US states. The company maintains all 50 US state licences for compounding, packaging, fulfilment, and shipping of prescription treatments, providing comprehensive national reach.
Under the proposed model, Strive Pharmacy will be responsible for the preparation, fulfilment, shipping, and related quality and supply chain operations for ROXUS. The company supports prescribers, clinics, and telehealth providers through its pharmacy fulfilment infrastructure and established clinic and provider network.
Strive Pharmacy’s operational capabilities include:
| Capability | Scope |
|---|---|
| Geographic coverage | All 50 US states |
| Platform | Multi-state 503A pharmacy operations across five states |
| Core services | Compounding, packaging, fulfilment, shipping |
| Quality operations | Supply chain management and quality assurance |
| Network access | Established clinic and provider relationships |
This national infrastructure eliminates the need for LTR Pharma to build pharmacy operations internally, reducing capital requirements and accelerating the launch timeline. The established clinic and provider network provides additional patient access opportunities beyond the company’s direct commercial channels.
How ROXUS® differentiates in the US erectile dysfunction market
ROXUS® is a rapid-acting intranasal treatment for erectile dysfunction that differentiates from oral PDE5 inhibitors such as Viagra and Cialis through its delivery mechanism and onset profile. The intranasal delivery suits on-demand patient behaviour and addresses patient preferences for faster onset and convenience.
The intranasal delivery mechanism’s commercial appeal is grounded in Phase II interim data showing a 10-minute median onset for the active compound, compared with 60 minutes for oral vardenafil, a pharmacokinetic profile that underpins ROXUS’s positioning as a genuinely differentiated option rather than a formulation variant of existing therapies.
LTR Pharma retains full ownership as the product owner, intellectual property holder, and formulation supplier. This commercial structure ensures the company captures the economic value of its proprietary technology whilst leveraging Strive Pharmacy’s operational infrastructure for fulfilment.
The product’s differentiation in a large, established market represents a commercial opportunity based on delivering improved patient experience rather than competing directly with generic oral therapies on price. The intranasal delivery mechanism addresses a subset of patients seeking alternatives to oral treatments or requiring faster onset of action.
Director commentary
Lee Rodne, Executive Chairman
“Executing this binding term sheet with Strive Pharmacy materially advances our US commercialisation strategy for ROXUS. Securing an experienced national pharmacy fulfilment partner is an important launch-readiness milestone and provides the operational infrastructure required to support commercial launch activities. Combined with our broader patient acquisition and market access initiatives, the arrangement supports LTR Pharma’s planned multi-channel approach to commercialising ROXUS in the United States.”
Michael Walker, President/Co-Founder, Strive Pharmacy
“We are excited to partner with LTR Pharma to support the introduction of ROXUS in the United States. ROXUS is an innovative addition to the men’s health category and aligns well with Strive Pharmacy’s focus on personalised medicine and patient-centric care. We look forward to working with the LTR Pharma team on launch readiness and the operational activities required to support patient access across the United States.”
The next major ASX story will hit our subscribers first
Next steps toward US commercial launch
The pathway to commercial launch requires sequential execution across defined milestones, providing near-term visibility on commercialisation progress.
Launch-readiness sequence:
- Definitive Agreements negotiation: Parties to execute Definitive Agreements within 30 days (extendable once by 30 days by mutual agreement)
- Technology transfer: Completion of formulation transfer and manufacturing processes to Strive Pharmacy’s facilities
- Pharmacy onboarding: Implementation of operational systems, quality procedures, and fulfilment infrastructure
- Launch-readiness conditions: Satisfaction of all technical and regulatory requirements for Commercial Launch
ROXUS will reach US consumers through a multi-channel commercialisation strategy incorporating telehealth, pharmacy fulfilment, and healthcare provider networks. This approach leverages multiple patient acquisition pathways rather than relying on a single distribution channel.
The Definitive Agreements execution and subsequent launch-readiness milestones provide near-term catalysts for investors monitoring commercialisation progress. Completion of these steps positions the company to begin revenue generation in the US market, which represents the world’s largest erectile dysfunction treatment market by value.
Want the Next Healthcare Breakthrough in Your Inbox?
Join 20,000+ investors receiving FREE breaking ASX healthcare news within minutes of release, complete with in-depth analysis. Click the “Free Alerts” button at Big News Blast to get real-time alerts the moment market-moving announcements drop across biotech, medtech, and pharma sectors.